Licensed vaccine
Fluad Quadrivalent
FDA-licensed vaccine · Seqirus, Inc. · STN 125510
Key facts
| Trade name | Fluad Quadrivalent |
|---|---|
| Proper name | Influenza Vaccine, Adjuvanted |
| Manufacturer | Seqirus, Inc. |
| Submission tracking number (STN) | 125510 |
| Recent FDA documents | June 30, 2023 Approval Letter - FLUAD QUADRIVALENT, February 24, 2023 Approval Letter - FLUAD QUADRIVALENT, July 1, 2022 Approval Letter - FLUAD QUADRIVALENT, July 2, 2021 Approval Letter - FLUAD, Statistical Review - FLUAD and FLUAD Quadrivalent, Clinical Review - FLUAD and FLUAD Quadrivalent, December 4, 2020 Approval Letter - FLUAD QUADRIVALENT, October 28, 2020 Approval Letter - Fluad and Fluad Quadrivalent, July 2, 2020 Approval Letter Fluad and Fluad Quadrivalent, Statistical Review - FLUAD QUADRIVALENT, February 20, 2020 Clinical Review - FLUAD QUADRIVALENT, Package Insert - FLUAD QUADRIVALENT |
| FDA page updated | Jul 3, 2023 |
| FDA product page | fda.gov |
At a glance
- 1–9 FDA approval letters
- 10–99 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: